Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2011 Mar 9:8:111.
doi: 10.1186/1743-422X-8-111.

Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review

Shu-Shan Zhao  1 , Lan-Hua Tang, Xia-Hong Dai, Wei Wang, Rong-Rong Zhou, Li-Zhang Chen, Xue-Gong Fan
Affiliations
Meta-Analysis

Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review

Shu-Shan Zhao et al. Virol J. .

Abstract

Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However, there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total, of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67), P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14], HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91), P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide evolving standards of care for chronic hepatitis B.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the studies identified.
Figure 2
Figure 2
Effect of TDF vs. ADV on HBV-DNA suppression at week 48.
Figure 3
Figure 3
Effect of TDF vs. ADV on HBV-DNA suppression in HBV-HIV subgroup at week 48.
Figure 4
Figure 4
Effect of TDF vs. ADV on ALT normalization at week 48.
Figure 5
Figure 5
Effect of TDF vs. ADV on ALT normalization in lamivudine-resistance subgroup at week 48.
Figure 6
Figure 6
Effect of TDF vs. ADV on HBeAg seroconversion rate at week 48.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Safioleas M, Lygidakis NJ, Manti C. Hepatitis B today. Hepatogastroenterology. 2007;54:545–548. - PubMed
    1. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351:2832–2838. doi: 10.1056/NEJMcp041507. - DOI - PubMed
    1. Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009;26:155–169. doi: 10.1007/s12325-009-0004-y. - DOI - PubMed
    1. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS. et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800–807. doi: 10.1056/NEJMoa021812. - DOI - PubMed
    1. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S. et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808–816. doi: 10.1056/NEJMoa020681. - DOI - PubMed

MeSH terms

LinkOut - more resources